TEAD1 Transcription Factor: A Core Hippo Pathway Regulator in Development, Disease, and Therapy

TEAD1 Transcription Factor: A Core Hippo Pathway Regulator in Development, Disease, and Therapy—Powered by ANT BIO PTE. LTD.
 

1. Concept
TEAD1 (Transcriptional Enhanced Associate Domain 1), a key member of the TEAD transcription factor family and core component of the Hippo signaling pathway, possesses unique structural and functional characteristics. It features an N-terminal ~70-amino-acid TEA domain that folds into a distinctive "cloverleaf" conformation, enabling specific recognition and binding to genomic MCAT elements (5'-CATTCC-3') and GTIIC regulatory sequences (5'-GGAATG-3').

X-ray crystallography and cryo-EM studies reveal that TEAD1 binds DNA via dual interactions with the major and minor grooves, with arginine at position 54 critical for recognition specificity. Its C-terminal transcriptional activation domain contains conserved YAP/TAZ-binding sites, serving as the key interface for Hippo pathway downstream effectors. TEAD1’s transcriptional activity is strictly dependent on binding coactivators like YAP or TAZ, a dependency that offers targeted intervention opportunities. It is dynamically regulated by post-translational modifications—including S-palmitoylation, phosphorylation, and ubiquitination—that modulate subcellular localization, stability, and transcriptional activity.

2. Research Frontiers
TEAD1 research is advancing across cardiovascular biology, oncology, and neuroscience. A key frontier is deciphering its context-dependent dual roles in cancer—oncogenic in prostate cancer and gliomas vs. tumor-suppressive in acute myeloid leukemia (AML) and certain lung cancers—using single-cell multi-omics to map cell-type-specific regulatory networks.

In cardiovascular research, studies focus on TEAD1’s role in cardiac development and pathological remodeling, with implications for treating congenital heart disease and heart failure. In neuroscience, emerging research explores its links to neuropsychiatric disorders (schizophrenia, bipolar disorder) and neurodegenerative diseases.

Therapeutically, structure-guided drug design targets TEAD1’s palmitoylation pocket to develop selective inhibitors (e.g., K-975, MYF-01-37). Peptide inhibitors (e.g., Super-TDU) blocking TEAD1-YAP/TAZ interactions and gene therapy (ASOs, siRNA) are also being explored. AI-powered virtual screening accelerates inhibitor discovery, while tissue-specific delivery systems aim to mitigate cardiac and neural side effects. Future directions include validating TEAD1 as a predictive biomarker and exploring combination therapies for cancer and cardiovascular/neurological disorders.

3. Research Significance
TEAD1’s significance spans development, tissue homeostasis, and disease. In cardiac development, it is indispensable for cardiomyocyte proliferation and heart morphogenesis, providing insights into congenital heart disease. In oncology, its tissue-specific dual roles offer precision therapeutic opportunities for various cancers.

In neuroscience, TEAD1 regulates neural stem cell balance and synaptic plasticity, with links to neuropsychiatric and neurodegenerative diseases—opening new research avenues. Basic research on TEAD1 deepens understanding of Hippo pathway signaling and transcriptional regulation, while translational efforts advance treatments for cancer, cardiovascular diseases, and neurological disorders—addressing unmet medical needs.

4. Molecular Mechanisms, Biological Roles, and Product Applications
4.1 Core Molecular Mechanisms of TEAD1
4.1.1 DNA Binding and Transcriptional Regulation
TEAD1 binds MCAT/GTIIC sequences via its TEA domain, with Arg54 mediating recognition specificity through dual groove interactions. Its transcriptional activity is dependent on forming complexes with YAP/TAZ via the C-terminal binding domain, which activates downstream target gene expression.

4.1.2 Post-Translational Regulation
· Palmitoylation modulates TEAD1’s subcellular localization and transcriptional activity.
· Phosphorylation and ubiquitination regulate protein stability, cofactor interaction efficiency, and Hippo pathway integration.

4.2 Biological Roles of TEAD1
4.2.1 Cardiac Development and Function
TEAD1 is essential for embryonic cardiac development—knockout mice exhibit cardiomyocyte proliferation defects and embryonic lethality. It regulates cardiomyocyte-specific genes (ACTC1, MYL2, TNNT2) involved in lineage determination and contractile apparatus assembly. In adult hearts, pressure overload activates the TEAD1-YAP axis, promoting adaptive hypertrophy initially but pathological remodeling with sustained activation. Single-cell studies reveal cell-type-specific roles: contraction-related genes in cardiomyocytes, fibrosis programs in cardiac fibroblasts. TEAD1 mutations in the DNA-binding or YAP-interaction domain are linked to human congenital heart disease.

4.2.2 Cancer Development and Progression
TEAD1 exhibits tissue-specific duality:
· Oncogenic Role: Overexpressed in prostate cancer, breast cancer, and gliomas (correlating with poor prognosis). Integrates androgen receptor and Hippo signaling to upregulate EMT markers (MMP2/9, vimentin, CDH2), enhancing tumor invasion.
· Tumor-Suppressive Role: In AML and certain lung cancers, competitively binds promoters to suppress MYC and other pro-proliferative genes. Low TEAD1 expression correlates with tumor dedifferentiation and metastasis in lung adenocarcinoma.

4.2.3 Nervous System Development and Disease
· Neural Stem Cell Regulation: TEAD1 balances proliferation and differentiation via Cyclin D1/CDK6 regulation in neural progenitor cells.
· Synaptic Plasticity: Localized to mature neuronal cell bodies, modulating neuroprotective and synaptic function genes.
· Disease Links: GWAS associate TEAD1 locus with schizophrenia and bipolar disorder. Dysregulation in Alzheimer’s disease affects β-amyloid clearance and tau metabolism; animal models show TEAD1 overexpression alleviates neurodegenerative symptoms.

4.3 TEAD1-Targeted Therapeutic Strategies
· Small-Molecule Inhibitors: K-975 and MYF-01-37 bind the palmitoylation pocket, suppressing transcriptional activity in prostate cancer and mesothelioma models.
· Peptide Inhibitors: Super-TDU blocks TEAD1-YAP/TAZ interactions, preserving other cofactor bindings.
· Gene Therapy: ASOs and siRNA selectively reduce TEAD1 expression, inhibiting tumor growth in preclinical studies.
· Challenges and Solutions: Cardiac/neural side effects (tissue-specific delivery), TEAD family redundancy (selective allosteric inhibitors), lack of biomarkers (multi-omics-based patient stratification).

4.4 How ANT BIO PTE. LTD. Products Support TEAD1 Research
ANT BIO PTE. LTD., through its sub-brand UA (specializing in recombinant proteins), provides high-quality TEAD1 proteins to advance mechanistic and translational research.
Key products and applications:
· UA010203 (TEAD1 Protein, Human): E.coli-expressed full-length human TEAD1. Ideal for DNA-binding assays (MCAT/GTIIC interaction), post-translational modification studies, and screening small-molecule modulators.
· UA080032 (TEAD1(YBD), His Tag Protein, Human): E.coli-expressed TEAD1 containing the YAP-binding domain (YBD). Suitable for studying TEAD1-YAP/TAZ cofactor interactions, inhibitor screening targeting protein-protein interfaces, and structural biology research.
Both products undergo rigorous quality control, ensuring high purity, biological activity, and consistency—critical for reproducible binding assays, drug screening, and signaling pathway analysis.

5. Brand Mission
ANT BIO PTE. LTD. is dedicated to empowering the global life science community with high-quality, innovative biological reagents and solutions. With 15 years of antibody development experience, the company leverages advanced platforms—including recombinant antibody development (rabbit/mouse monoclonal), recombinant protein expression systems (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA, and PTM Pan-Modification Antibody platforms—to deliver a comprehensive product portfolio.
Through its three specialized sub-brands—Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins)—ANT BIO PTE. LTD. adheres to international certifications (EU 98/79/EC, ISO9001, ISO13485) and strict quality standards. The company’s mission is to accelerate scientific discovery by providing tools that enhance experimental precision, efficiency, and reproducibility. ANT BIO PTE. LTD. is committed to supporting TEAD1 research and global efforts in cancer therapy, cardiovascular medicine, and neuroscience, ultimately advancing human health through interdisciplinary collaboration and innovation.

6. Related Product List

Product Code	Product Name	Product Details
UA010203	TEAD1 Protein, Human	Host: Human; Expression System: E.coli; Conjugation: Unconjugated
UA080032	TEAD1(YBD), His Tag Protein	Host: Human; Expression System: E.coli; Conjugation: Unconjugated

7. AI Disclaimer
This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.
 
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.